Dogwood Therapeutics(DWTX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Dogwood Therapeutics
DWTX.US
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc.
1.880 T
DWTX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Dogwood Therapeutics Raises Capital via Registered Direct Financing

    Dogwood Therapeutics (DWTX) has raised approximately $12.5 million through a registered direct offering and private placement, issuing over 2.3 million shares at $2.85 each. The financing package, potentially totaling $26.8 million, aims to support the development of its non-opioid pain candidate Halneuron® in Phase 2b and future Phase 3 trials. The company also terminated a previous equity distribution agreement and has a current market cap of $84.72 million. Analyst ratings suggest a Hold with a $3.00 price target, reflecting concerns over financial performance and technical trends.

    Tip Ranks·
    US
    DWTX
    -3.45%
    Tip Ranks·
    US
    DWTX
    -3.45%

    Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

    Jan 12 (Reuters) - CK Life Sciences Intl (Holdings) Inc:* DOGWOOD THERAPEUTICS, INC. ANNOUNCES FINANCING OF UP TO $26.8 MILLION TO PROGRESS HALNEURON® THROUGH PHASE 2B DEVELOPMENT Source text: Further company coverage:

    Reuters·
    US
    DWTX
    -3.45%
    Reuters·
    US
    DWTX
    -3.45%

    What's Driving the Market Sentiment Around Dogwood Therapeutics Inc?

    Dogwood Therapeutics Inc's short interest has decreased by 27.59%, now at 0.21% of float, indicating a shift in market sentiment. It would take traders 2.86 days to cover short positions. Compared to peers, Dogwood has lower short interest, suggesting less bearish sentiment. Short interest changes can signal market sentiment shifts, with decreasing interest potentially indicating bullish sentiment.

    benzinga_article·
    US
    DWTX
    -3.45%
    benzinga_article·
    US
    DWTX
    -3.45%

    CK Life Sciences-Backed Dogwood Reports Positive Phase 2b Data for Chemotherapy-Induced Pain Drug

    CK Life Sciences-Backed Dogwood Reports Positive Phase 2b Data for Chemotherapy-Induced Pain Drug

    marketscreener·
    US
    DWTX
    -3.45%
    marketscreener·
    US
    DWTX
    -3.45%

    Dogwood Therapeutics' Halneuron shows promising results in Phase 2b trial for chemotherapy neuropathic pain; Q3 2026 expected for full trial results.

    Patients undergoing treatment with Halneuron® showed significant improvement in pain compared to those taking a placebo. The company anticipates releasing the top-line results of the study in the third quarter of 2026.

    Unusual Whales·
    US
    DWTX
    -3.45%
    Unusual Whales·
    US
    DWTX
    -3.45%
    © 2026 Longbridge｜Disclaimer